Indi Molecular is a pioneering brand specializing in small molecule oncology therapeutics. Their groundbreaking Protein Catalyzed Capture (PCC) agents have enabled the development of synthetic targeted therapeutics for ovarian cancer and pancreatic cancers expressing the KRAS G12D mutation. These therapeutics are innovative peptide-based alternatives to traditional antibody-based treatments.

One of their notable products is the Indi 177 Lu-7327 molecule, an ultra-high affinity folate receptor targeting molecule that delivers its therapeutic payload with remarkable precision. It possesses a unique property that allows for higher therapeutic dosing while sparing the renal system. This molecule has recently undergone FDA pre-IND review.

Another remarkable product offered by Indi Molecular is Indi-344, which specifically targets the mutated KRAS G12D oncogene in pancreatic cancer cells. It effectively inhibits the oncogene's function by binding to its switch region. The brand prides itself on the specificity and binding affinities of its molecules, which are achieved through careful epitope selection and cooperative binding.

Indi Molecular's small peptides are also known for their solubility, stability, and rapid synthesis capabilities, making them efficient in manufacturing. With their in vivo functional activity, Indi Molecular's PCC agents have proven their ability to deliver therapeutic effects against both intra and extracellular targets. In recent news, Indi Molecular, in collaboration with the Institute for Systems Biology, has been granted a patent for their KRAS-specific cyclic peptides.

The brand continues to make strides in the field and has closed the sale of their advanced PCC technology platform while retaining two powerful molecules targeting ovarian and pancreatic cancer. Indi Molecular is located at 5877 Obama Blvd, Los Angeles, CA 90016, and is committed to revolutionizing oncology therapeutics through innovative small molecule solutions